Castro-Martín Eduardo, Galiano-Castillo Noelia, Fernández-Lao Carolina, Ortiz-Comino Lucía, Postigo-Martin Paula, Arroyo-Morales Manuel
Department of Physical Therapy, Faculty of Health Sciences, University of Granada, 18016 Granada, Spain.
Sport and Health University Research Institute (iMUDS), 18016 Granada, Spain.
J Clin Med. 2021 Oct 27;10(21):5003. doi: 10.3390/jcm10215003.
Head and neck cancer (HNC) is the sixth most common cancer worldwide. Yet, less than 60% of HNC survivors receive adequate therapy for treatment-related sequelae. The objective of this study was to determine the efficacy of myofascial induction therapy (MIT) in improving cervical and shoulder pain and range of motion, maximal mouth opening, and cervical muscle function in HNC survivors. This crossover, blinded, placebo-controlled study involved 22 HNC survivors (average age 56.55 ± 12.71) of which 13 were males (59.1%) who received, in a crossover fashion, both a single 30-min session of MIT in the form of manual unwinding and simulated pulsed shortwave therapy (placebo), with a 4-week washout interval between the two. Cervical and shoulder pain (visual analogue scale) and range of motion (cervical range of motion device and goniometer), maximum mouth opening (digital caliper), and cervical muscle function (deep cervical flexor endurance test) were measured before and after the treatment and placebo sessions. A single session of MIT improved cervical and affected side shoulder pain, cervical range of motion, maximum mouth opening, and cervical muscle function. The associated effect sizes ranged from moderate to large. The present study suggests that MIT, in the form of manual unwinding, improves cervical (-3.91 ± 2.77) and affected-side shoulder (-3.64 ± 3.1) pain, cervical range of motion (flexion: 8.41 ± 8.26 deg; extension: 12.23 ± 6.55; affected-side rotation: 14.27 ± 11.05; unaffected-side rotation: 11.73 ± 8.65; affected-side lateroflexion: 7.95 ± 5.1; unaffected-side lateroflexion: 9.55 ± 6.6), maximum mouth opening (3.36 ± 3.4 mm), and cervical muscle function (8.09 ± 6.96 s) in HNC survivors.
头颈癌（HNC）是全球第六大常见癌症。然而，不到60%的头颈癌幸存者接受了针对治疗相关后遗症的充分治疗。本研究的目的是确定肌筋膜诱导疗法（MIT）在改善头颈癌幸存者的颈部和肩部疼痛、活动范围、最大张口度以及颈部肌肉功能方面的疗效。这项交叉、双盲、安慰剂对照研究纳入了22名头颈癌幸存者（平均年龄56.55±12.71岁），其中13名男性（59.1%），他们以交叉方式接受了一次30分钟的MIT（以手动放松的形式）和模拟脉冲短波疗法（安慰剂），两次治疗之间有4周的洗脱期。在治疗和安慰剂治疗前后，测量了颈部和肩部疼痛（视觉模拟量表）、活动范围（颈部活动范围测量仪和角度计）、最大张口度（数字卡尺）以及颈部肌肉功能（颈深屈肌耐力测试）。单次MIT治疗改善了颈部和患侧肩部疼痛、颈部活动范围、最大张口度以及颈部肌肉功能。相关效应大小从中度到高度不等。本研究表明，以手动放松形式进行的MIT可改善头颈癌幸存者的颈部（-3.91±2.77）和患侧肩部（-3.64±3.1）疼痛、颈部活动范围（前屈：8.41±8.26度；后伸：12.23±6.55；患侧旋转：14.27±11.05；健侧旋转：11.73±8.65；患侧侧屈：7.95±5.1；健侧侧屈：9.55±6.6）、最大张口度（3.36±3.4毫米）以及颈部肌肉功能（8.09±6.96秒）。
